2024
1896-LB: Clinical Features and C-Peptide Levels Associated with Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Dapagliflozin vs. Placebo—Insights from DECLARE-TIMI 58
MI KANG Y, MELLONI G, CAHN A, RAZ I, MOURA F, BHATT D, INZUCCHI S, LEITER L, MCGUIRE D, WILDING J, GAUSE-NILSSON I, OSCARSSON J, MARSTON N, RUFF C, SABATINE M, WIVIOTT S. 1896-LB: Clinical Features and C-Peptide Levels Associated with Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Dapagliflozin vs. Placebo—Insights from DECLARE-TIMI 58. Diabetes 2024, 73 DOI: 10.2337/db24-1896-lb.Peer-Reviewed Original ResearchDuke Clinical Research InstituteC-pepClinical Research InstituteDKA eventsC-peptideLower fasting C-peptideMedian follow-upRandomized to dapagliflozinFasting C-peptideDuration of T2DC-peptide testingRisk of DKACV outcome trialsAmerican College of CardiologyAbsolute risk differenceRate of DKAImpaired insulin secretionType 2 diabetesPlacebo armClinical featuresPopulation Health Research InstituteCSL BehringDiabetic ketoacidosisFerring PharmaceuticalsOutcome trials
2021
Abstract 13182: Dapagliflozin and Changes in Metabolic Syndrome in Patients With Type 2 Diabetes: A DECLARE TIMI 58 Sub-Analysis
Moura F, Itamar R, Cahn A, Goodrich E, Bhatt D, Leiter L, WILDING J, Gause-nilsson I, Mosenzon O, Sabatine M, Wiviott S. Abstract 13182: Dapagliflozin and Changes in Metabolic Syndrome in Patients With Type 2 Diabetes: A DECLARE TIMI 58 Sub-Analysis. Circulation 2021, 144: a13182-a13182. DOI: 10.1161/circ.144.suppl_1.13182.Peer-Reviewed Original ResearchHDL-CMetabolic syndromeProgression to MetSAssociation of MetSClassification of MetSPrevalence of MetSHDL-C <Prediction of CV deathRandomized to dapagliflozinComponents of MetSPresence of MetSEffects of dapagliflozinLow HDL-CType 2 diabetes mellitusFollow-up visitAssociated with outcomeType 2 diabetesIDF criteriaBaseline characteristicsCV deathSGLT2 inhibitorsDapagliflozin armHeart failureSub-analysisElevated BP